TFF Pharmaceuticals Inc (Nasdaq:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercialising drug products based on its Thin Film Freezing (TFF) technology platform, announced on Wednesday that it has partnered with Emory University and the Biomedical Advanced Research and Development Authority (BARDA) to develop a dry powder inhaled mRNA-based treatment for influenza and COVID-19.

This partnership aims to leverage TFF's technology to improve the delivery, stability and distribution of the mRNA-based antiviral.

The project is supported by a BARDA contract under its Flexible and Strategic Therapeutics (FASTx) programme, which focuses on developing rapid antiviral platforms to combat emerging viral threats.